Advertisement
Advertisement
ACRS
Aclaris Therapeutics, Inc.
4.93
USDSponsored
+0.07
+1.44%
May 08, 15:59 UTC -4
Closed
Pre-Market
4.92
0.00
-0.10%
ACRS Earnings Reports
Positive Surprise Ratio
ACRS beat 28 of 41 last estimates.
68%
Next Report
Tomorrow
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.26M
/-$0.16
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
-13.29%
/+33.33%
Aclaris Therapeutics, Inc. earnings per share and revenue
On --, ACRS reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.16 USD, with revenue projected to reach 1.26 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Aclaris Therapeutics, Inc.'s earnings and revenue for the latest quarter Q-- --?
For Q-- --, Aclaris Therapeutics, Inc. reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.
How did the market react to Aclaris Therapeutics, Inc.'s Q-- -- earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Aclaris Therapeutics, Inc. expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Aclaris Therapeutics, Inc.'s next earnings report?
Based on 6
analysts, Aclaris Therapeutics, Inc. is expected to report EPS of -$0.16 and revenue of $1.26M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement